PRA Health Sciences
A former global contract research organization headquartered in Raleigh, North Carolina, providing clinical development and related research services to the biopharmaceutical industry.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
PRA Health Sciences was a contract research organization (CRO) serving pharmaceutical, biotechnology, and other life-sciences clients. Headquartered in Raleigh, North Carolina, the company supported the development of medicines through outsourced clinical research and related services. Its work covered areas such as clinical trial execution, clinical development, data management, and regulatory support, positioning PRA as an external partner for sponsors that needed to plan, manage, analyze, and report studies across multiple markets. The business originated in 1976 as the Anti-Inflammatory Drug Study Group. Its initial identity reflected a focus on anti-inflammatory medicines, but the organization broadened its therapeutic scope as it expanded. In 1982 it adopted the name PRA, marking a transition from a narrowly defined study group toward a more diversified research-services organization. Over time, PRA developed into a global CRO capable of supporting programs beyond a single therapeutic category or geography. A major ownership change occurred in 2013, when the investment firm Kohlberg Kravis Roberts acquired the company. Under that ownership, PRA returned to the public markets in November 2014. KKR retained its shareholding until September 2019. The public-company period formed part of PRA's expansion as a scaled CRO, while also subjecting the business to the reporting and market expectations associated with a listed enterprise. PRA broadened its capabilities through acquisition as well as organic development. In August 2017, it purchased Symphony Health, a Conshohocken-based provider of real-world healthcare data, analytics, and technology solutions, for approximately $530 million. The transaction added data and analytics capabilities that complemented conventional clinical research services and strengthened PRA's ability to work with healthcare information outside the immediate trial setting. PRA reported revenue of approximately $2.87 billion for 2018, according to the cited Wikipedia reference. The company ceased to operate as an independent publicly traded CRO when ICON plc completed its acquisition of PRA on July 1, 2021. Following the transaction, PRA became part of ICON's broader clinical research organization. As a result, PRA Health Sciences is best treated as a former standalone corporate brand and operating business rather than an active independent company. Its historical significance lies in the growth of a specialized anti-inflammatory study group into a large, international CRO, the integration of real-world data capabilities through Symphony Health, and its eventual combination with ICON.
History
PRA Health Sciences began in 1976 as the Anti-Inflammatory Drug Study Group, an organization established to conduct studies involving anti-inflammatory medicines. The initial name described its therapeutic emphasis, but the company did not remain limited to that field. As its activities expanded into other therapeutic areas, it adopted the shorter name PRA in 1982. This change reflected the development of a broader contract research platform rather than a single-purpose study organization. Over the following decades, PRA developed as an outsourced research partner for pharmaceutical and biotechnology companies. Like other CROs, it enabled sponsors to delegate parts of the medicine-development process, including the planning and execution of clinical studies, management of trial information, and support for regulatory submissions. Its business model was based on providing specialized personnel, processes, and infrastructure that could be used across therapeutic programs and national markets. In 2013, Kohlberg Kravis Roberts acquired PRA. The transaction placed the CRO under private-equity ownership and preceded its return to the public markets. PRA was publicly listed in November 2014, while KKR continued to hold shares until September 2019. The period combined organizational expansion with the obligations of being a public company, including greater visibility into corporate performance and strategy. PRA expanded its service mix in August 2017 through the acquisition of Symphony Health for approximately $530 million. Symphony Health was based in Conshohocken and specialized in real-world healthcare data, analytics, and technology solutions. Integrating these capabilities gave PRA a stronger connection to evidence generated outside traditional randomized clinical trials and added information-management and analytical resources to its clinical research platform. The company reported approximately $2.87 billion in revenue in 2018, according to the cited Wikipedia article. By then, PRA had evolved from its original anti-inflammatory focus into a substantial international CRO with a broad clinical-development and data-services offering. The final major stage in PRA's corporate history was its acquisition by ICON plc. ICON completed the transaction on July 1, 2021. After completion, PRA no longer operated as an independent company. Its capabilities and operations were incorporated into ICON, making PRA Health Sciences a former standalone CRO brand. The company's history therefore traces a path from a focused therapeutic study group, through diversification, private-equity ownership and public listing, to data-oriented expansion and ultimate integration into another global CRO.
- 2021
Acquired by ICON plc
[1]ICON plc completed its acquisition of PRA Health Sciences on July 1, 2021.
- 2019
KKR shareholding ended
[1]Kohlberg Kravis Roberts maintained shares in PRA until September 2019.
- 2017
Symphony Health acquisition
[1]PRA acquired Symphony Health to add real-world healthcare data, analytics, and technology capabilities.
- 2014
Public listing
[1]PRA became publicly listed in November 2014.
- 2013
Acquired by Kohlberg Kravis Roberts
[1]Kohlberg Kravis Roberts acquired PRA, initiating a period of private-equity ownership.
- 1982
Organization renamed PRA
[1]The company adopted the PRA name as it expanded beyond its original anti-inflammatory research focus.
- 1976
Anti-Inflammatory Drug Study Group established
[1]The organization that would become PRA Health Sciences was established as the Anti-Inflammatory Drug Study Group.
Products and positioning
Global contract research organization providing outsourced clinical development, trial-management, data, analytics, and regulatory services to life-sciences sponsors.
Contract research services
Clinical trial services
PRA's core offering was the outsourced support of clinical trials for pharmaceutical and biotechnology sponsors. The service platform covered the operational work required to organize and conduct studies, coordinate research activities, and support programs across multiple sites and markets. It formed the foundation of PRA's identity as a global contract research organization.
Drug development
Clinical development services
PRA provided broader clinical-development support beyond individual trial activities. These services helped sponsors advance investigational medicines through development programs, combining study execution with planning, operational coordination, and related development expertise across therapeutic areas.
Healthcare data services · 2017
Data management and analytics
Data management and analytical capabilities supported the collection, organization, interpretation, and reporting of information generated during clinical research. PRA strengthened this area through its acquisition of Symphony Health, whose real-world healthcare data and analytics capabilities expanded the company's information-services offering.
Regulatory services
Regulatory consulting
PRA's service portfolio included regulatory support for life-sciences sponsors. Regulatory work in a CRO context can connect clinical-development evidence with submission and compliance requirements, helping clients prepare and manage the documentation and interactions associated with medicine development.
Controversies
2021
Shareholder sues PRA Health Sciences over proposed ICON merger disclosures
Michael Birdsall filed suit against PRA Health Sciences and its Board of Directors, alleging that the company provided shareholders with misleading information about its proposed merger with ICON, including through a materially incomplete and misleading proxy statement. The plaintiff sought injunctive and other equitable relief.
Brand decisions
2021
Combine with ICON plcM&ABackground
PRA was an established global CRO, while ICON was pursuing a larger clinical research platform through acquisition.
Action taken
ICON plc completed its acquisition of PRA Health Sciences on July 1, 2021.
Aftermath
PRA ceased to operate as an independent company and became part of ICON's broader organization.
2017
Acquire Symphony HealthM&ABackground
PRA sought to broaden its clinical research platform with real-world healthcare data, analytics, and technology capabilities.
Action taken
PRA acquired Symphony Health in August 2017 for approximately $530 million.
Aftermath
The transaction added a data and analytics business to PRA's CRO offering and supported a broader evidence and information-services proposition.
Acquisition price. 530 million USD (August 2017)
Recent events
Shareholder sues PRA Health Sciences over proposed ICON merger disclosures[2]
Reported:
Michael Birdsall filed suit against PRA Health Sciences and its Board of Directors, alleging that the company provided shareholders with misleading information about its proposed merger with ICON, including through a materially incomplete and misleading proxy statement. The plaintiff sought injunctive and other equitable relief.
Phlexglobal and PRA implement Global TMF Center of Excellence[3]
Reported:
Phlexglobal announced the successful creation and implementation of a Global TMF Center of Excellence with partner PRA Health Sciences, using Phlexglobal technology and expertise.
PRA Health Sciences launches COVID-19 Monitoring Program[4]
Reported:
PRA Health Sciences announced the commercial availability of a mobile-app-driven COVID-19 Monitoring Program for employers, payers, providers and health systems to monitor individuals' health and wellbeing.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/pra-health-sciences · Editorial policy · How profiles are compiled